Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

SELL
$3.18 - $4.9 $44 - $68
-14 Reduced 31.82%
30 $0
Q3 2023

Nov 03, 2023

BUY
$2.97 - $3.88 $130 - $170
44 New
44 $0

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $357M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Signaturefd, LLC Portfolio

Follow Signaturefd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.